Randomized, Placebo-controlled, Observer-blinded Phase 1 Safety and Immunogenicity Study of Inactivated Zika Virus Vaccine Candidate in Healthy Adults

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 24, 2018

Primary Completion Date

June 26, 2018

Study Completion Date

November 16, 2018

Conditions

Zika VirusZika Virus Infection

Interventions

BIOLOGICAL

VLA1601

purified inactivated ZIKV vaccine candidate adsorbed on alum

BIOLOGICAL

Placebo

Phosphate buffered saline (PBS)

Trial Locations (1)

New Orleans Center for Clinical Research, Knoxville